The DOI matches its Crossref record.
Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV
Open accessAbstract
Recently, the World Health Organization (WHO) has declared the novel coronavirus (2019-nCoV) outbreak a Public Health Emergency of International Concern (PHEIC), which is now formally named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of 27 February 2020, a total of 82,178 cases of SARS-CoV-2 infection have been confirmed across the world, with 78,630 cases in China (https://ncov.dxy.cn/ncovh5/view/pneumonia?source=). The SARSCoV-2 has been determined as the seventh member of the coronaviruses infected humans. Moreover, similar to severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), the SARS-CoV-2 could also cause severe and fatal illness. Since the SARS-CoV-2 outbreak, there have been approximately 14,792 clinically severe cases and 2800 dead cases. Due to the fast spread of SARS-CoV-2 and shortage of specific therapy, many efforts have focused on neutralizing antibody and vaccine development. Vaccines prevent disease largely depending on inducing neutralizing antibodies against vulnerable epitopes on antigen. Among the structural proteins of coronavirus, the spike glycoprotein contains receptor-binding domain (RBD) to mediate coronavirus entering host cells, which makes spike protein the primary antigenic target of neutralizing antibody and vaccine. Recently, it has been reported that the genome of SARS-CoV-2 have 79.5% nucleotide sequence identify to that of SARS-CoV. The genome relatedness indicates the possibilities that pre-clinical drugs against SARS-CoV might be effective to SARS-CoV-2. Also, a recent study was focused on cross-protective epitope between the spike proteins of SARS-CoV-2 and SARS-CoV, and successfully found the cross-protective epitopes in the RBDs of the spike proteins. Moreover, another study found that the spike RBD of SARS-CoV-2 bound potently to angiotensin-converting enzyme 2 (ACE2), the host cell receptor of SARS-CoV. However, in spite of the same binding target to ACE2, three of four monoclonal antibodies capable of binding potently to the SRAS-CoV RBD failed to show evident binding to the SARS-CoV-2 RBD. The limited antibody cross-reactivity suggests the importance to investigate the difference of antibody epitopes between the spike proteins of SARS-CoV and SARS-CoV-2. In our study, we found the SARS-CoV-2 spike protein had approximately 24.5% amino acid (a.a.) sequence non-conserved to that of SARS-CoV (Supplementary Fig. 1). Because of the divergence of spike proteins, the non-conserved regions of spike proteins might have the main responsibility for the antigenic difference. Thus, to solve the problem, we conducted antibody epitope analysis that focused on the comparison of the conserved and non-conserved regions of spike glycoproteins between MERSCoV, SRAS-CoV, and SARS-CoV-2. The spike proteins of SARS-CoV-2 from Wuhan, Zhejiang, and Guandong in China and other countries of the United States, France, Australia, and Germany were nearly 100% conserved (Supplementary Fig. 2). Next, alignment and phylogenetic analysis of the amino acid sequences of spike proteins in SARS-CoV-2, MERS-CoV, and SARS-CoVs showed the difference of sequence conservancy (Fig. 1a and Supplementary Fig. 1). As spike proteins of those five SARS-CoVs had approximately 99.5% homologous a.a. sequence (Supplementary Fig. 2), we used SARS-NS1 as a representative SARS-CoV for further analysis. Currently, bioinformatic approaches of epitope analysis are welldeveloped and successfully proved to identify both weak and strong epitopes that might be experimentally ignored. In our study, using antibody epitope bioinformatic tools (Supplementary Materials and Methods), we computed sequence-based antibody epitope scores in spike proteins of MERS-CoV, SARS-CoV, and SARS-CoV-2 (Fig. 1b). The SARS-CoV-2 had significantly lower antibody epitope score compared with MERS-CoV (p < 0.0001; Fig. 1c) and significantly higher antibody epitope score compared with SARS-CoV (p < 0.01; Fig. 1c), indicating the spike proteins have significantly variable antigenicity. Next, we conducted sequence alignment to acquire the conserved and nonconserved regions of spike proteins (Fig. 1d and Supplementary Fig. 1). Compared with the conserved regions, the non-conserved regions had significantly higher antibody epitope score (Fig. 1e, f), indicating the non-conserved regions of spike proteins are more antigenic. As the surface accessibility of epitope is also important for the interaction of antibody and antigen, we evaluated the surface epitope accessibility of spike proteins (Fig. 1g), no significant difference was observed in the total protein level (Fig. 1h). However, non-conserved regions showed significantly higher surface epitope accessibility score (Fig. 1i, j), indicating the nonconserved regions of spike proteins are more available for antibody recognition. Furthermore, we identified the antibody epitopes considering both the antibody epitope and surface epitope accessibility scores (Fig. 1k and Supplementary Materials and Methods). The antibody epitopes of spike proteins were compared between MERS-CoV, SARS-CoV, and SARS-CoV-2 (Fig. 1l), and the unique, shared, and public epitopes were identified (Fig. 1m). No public epitope could be found. Although five epitopes were shared between SARS-CoV and SARS-CoV-2, there were apparent dominances of unique epitopes in SRAS-CoV (83.9%) and SRAS-CoV-2 (85.3%) (Fig. 1n).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Huang, Y., Yang, C., Xu, X.-F., Xu, W., & Liu, S.-W. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0485-4 · Cited by 2,224
Immunology of COVID-19: Current State of the Science
Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.002 · Cited by 1,623
COVID-19: A promising cure for the global panic
Vellingiri, B., Jayaramayya, K., Iyer, M., Narayanasamy, A., Govindasamy, V., Giridharan, B., Ganesan, S., Venugopal, A., Venkatesan, D., Ganesan, H., et al. (2020) · Science of The Total Environment · doi:10.1016/j.scitotenv.2020.138277 · Cited by 636
Treatment with convalescent plasma for COVID‐19 patients in Wuhan, China
Ye, M., Fu, D., Ren, Y., Wang, F., Wang, D., Zhang, F., Xia, X., & Lv, T. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25882 · Cited by 410
Poh, C. M., Carissimo, G., Wang, B., Amrun, S. N., Lee, C. Y.-P., Chee, R. S.-L., Fong, S.-W., Yeo, N. K.-W., Lee, W.-H., Torres-Ruesta, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16638-2 · Cited by 396
Metadata
- Authors
- Zheng, M., & Song, L.
- Venue
- Cellular & Molecular Immunology
- Published
- 2020-03-04
- Volume
- 17
- Issue
- 5
- Pages
- 536-538
- ISSN
- 1672-7681 (ISSN-L)
- 2042-0226
- OpenAlex
- W3010238729
- Cited by
- 177
- References
- 0
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV. https://app.cochat.ai/papers/10.1038/s41423-020-0385-z
- The paper
- Zheng, M., & Song, L. (2020). Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV. Cellular & Molecular Immunology. https://doi.org/10.1038/s41423-020-0385-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.